Cargando…
A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
SIMPLE SUMMARY: Neoadjuvant chemotherapy is now a standard of care not only to decrease tumor size for breast conserving operation but also to assess drug response of an in situ cancer. Although the triple-negative subtype typically responds better compared to the other subtypes, a pathological comp...
Autores principales: | Oshi, Masanori, Angarita, Fernando A., Tokumaru, Yoshihisa, Yan, Li, Matsuyama, Ryusei, Endo, Itaru, Takabe, Kazuaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156144/ https://www.ncbi.nlm.nih.gov/pubmed/34065619 http://dx.doi.org/10.3390/cancers13102401 |
Ejemplares similares
-
ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020) -
Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020) -
Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival
por: Oshi, Masanori, et al.
Publicado: (2021) -
CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020) -
Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients
por: Oshi, Masanori, et al.
Publicado: (2020)